[go: up one dir, main page]

DE60336811D1 - Neue benzimidazolderivate - Google Patents

Neue benzimidazolderivate

Info

Publication number
DE60336811D1
DE60336811D1 DE60336811T DE60336811T DE60336811D1 DE 60336811 D1 DE60336811 D1 DE 60336811D1 DE 60336811 T DE60336811 T DE 60336811T DE 60336811 T DE60336811 T DE 60336811T DE 60336811 D1 DE60336811 D1 DE 60336811D1
Authority
DE
Germany
Prior art keywords
benzimidazole derivatives
new benzimidazole
new
derivatives
benzimidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60336811T
Other languages
English (en)
Inventor
Norikazu Otake
Minoru Moriya
Yoshio Ogino
Kenji Matsuda
Yoshikazu Nagae
Akio Kanatani
Takehiro Fukami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD KK
Original Assignee
MSD KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSD KK filed Critical MSD KK
Application granted granted Critical
Publication of DE60336811D1 publication Critical patent/DE60336811D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60336811T 2002-06-28 2003-06-26 Neue benzimidazolderivate Expired - Lifetime DE60336811D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002190978 2002-06-28
PCT/JP2003/008161 WO2004002986A2 (en) 2002-06-28 2003-06-26 Novel benzimidazole derivatives

Publications (1)

Publication Number Publication Date
DE60336811D1 true DE60336811D1 (de) 2011-06-01

Family

ID=29996905

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60336811T Expired - Lifetime DE60336811D1 (de) 2002-06-28 2003-06-26 Neue benzimidazolderivate

Country Status (23)

Country Link
US (3) US7105526B2 (de)
EP (1) EP1517908B1 (de)
CN (2) CN100427486C (de)
AR (1) AR040271A1 (de)
AT (1) ATE506360T1 (de)
AU (1) AU2003248248B2 (de)
BR (1) BR0312066A (de)
CA (1) CA2490722C (de)
DE (1) DE60336811D1 (de)
DO (1) DOP2003000662A (de)
EA (1) EA200500103A1 (de)
EC (1) ECSP045505A (de)
HR (1) HRP20041218A2 (de)
IL (1) IL165810A0 (de)
IS (1) IS7667A (de)
MX (1) MXPA04012731A (de)
NO (1) NO20050184L (de)
PE (1) PE20040583A1 (de)
PL (1) PL374693A1 (de)
RS (1) RS113704A (de)
TW (1) TW200406411A (de)
WO (1) WO2004002986A2 (de)
ZA (1) ZA200409339B (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6374762B1 (en) * 1997-10-27 2002-04-23 Correct Craft, Inc. Water sport towing apparatus
ATE433971T1 (de) * 2002-11-29 2009-07-15 Banyu Pharma Co Ltd Neue azolderivate
JP2006519229A (ja) * 2003-02-13 2006-08-24 アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ 視床下部内の長鎖脂肪アシルＣｏＡレベルの変調による摂食量およびグルコース産生量の調節
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US20040242566A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
ZA200602051B (en) 2003-08-13 2007-10-31 Takeda Pharmaceutical 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
US7825235B2 (en) * 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US20060019954A1 (en) * 2004-07-20 2006-01-26 Cedars-Sinai Medical Center Method for reducing the likelihood of the occurrence of cardiac arrhythmias
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
EP2364705A3 (de) * 2004-08-19 2012-04-04 Vertex Pharmaceuticals Incorporated Modulatoren von muskarinischen Rezeptoren
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US7863449B2 (en) * 2004-11-29 2011-01-04 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2006088875A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Intranasal administration of modulators of hypothalamic atp-sensitive potassium channels
PE20070522A1 (es) 2005-09-14 2007-07-11 Takeda Pharmaceutical 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo como inhibidor de dipeptidil peptidasa y composiciones farmaceuticas que lo contienen
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
US7822474B2 (en) * 2005-11-30 2010-10-26 Cedars-Sinai Medical Center Methods for the prediction of arrhythmias and prevention of sudden cardiac death
AU2006330866A1 (en) * 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP1988892A2 (de) * 2006-02-22 2008-11-12 Vertex Pharmaceuticals Incorporated Modulatoren muskarinischer rezeptoren
EP1987034B1 (de) * 2006-02-22 2011-07-20 Vertex Pharmceuticals Incorporated Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren
WO2007104053A2 (en) * 2006-03-09 2007-09-13 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2040706A2 (de) * 2006-06-29 2009-04-01 Vertex Pharmceuticals Incorporated Modulatoren muskarinischer rezeptoren
US8003620B2 (en) * 2006-08-04 2011-08-23 Isis Pharmaceuticals, Inc. Compositions and their uses directed to diacylglycerol acyltransferase 1
CA2660903A1 (en) * 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CA2660974A1 (en) 2006-08-18 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
EP2083831B1 (de) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Verfahren zur behandlung von fettsäure-synthese-hemmern
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
MX2010003373A (es) * 2007-10-03 2010-04-30 Vertex Pharma Moduladores de receptores muscarinicos.
US20090281143A1 (en) * 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
CA2724774C (en) 2008-05-28 2013-06-25 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
MX2011008982A (es) 2009-02-27 2011-09-15 Enata Pharmaceuticals Inc Inhibidores del virus de la hepatitis c.
KR101550557B1 (ko) 2009-11-10 2015-09-04 화이자 인코포레이티드 N1-피라졸로스피로케톤 아세틸-coa 카복실라아제 억제제
US8530648B2 (en) 2009-12-21 2013-09-10 Novartis Ag Diaza-spiro[5.5]undecanes
EP2374731A1 (de) 2010-04-07 2011-10-12 Altachem N.V. Hochleistungsventil
WO2012042433A1 (en) 2010-09-30 2012-04-05 Pfizer Inc. N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
DK2632925T3 (en) 2010-10-29 2015-06-29 Pfizer N1 / N2-lactam acetyl-CoA carboxylase inhibitors
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CN106117205B (zh) 2011-04-22 2018-09-21 辉瑞大药厂 用作乙酰辅酶a羧化酶抑制剂类的吡唑并螺酮衍生物
KR20140040801A (ko) 2011-07-15 2014-04-03 시오노기세야쿠 가부시키가이샤 Ａｍｐｋ 활성화 작용을 갖는 아자벤즈이미다졸 유도체
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA2991894A1 (en) 2015-07-10 2017-01-19 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (dgat2)
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4010314B1 (de) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl-pyrrolidin- und piperidinorexinrezeptor-agonisten
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN115835908A (zh) 2019-10-14 2023-03-21 因赛特公司 作为fgfr抑制剂的双环杂环
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505257A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
IL300610A (en) 2020-08-18 2023-04-01 Merck Sharp ַ& Dohme Llc Bicycloheptane pyrrolidine compounds are orexin receptor agonists
US11683717B2 (en) * 2020-11-09 2023-06-20 Celona, Inc. Method and apparatus for determining wireless MNO coverage and efficiently operating an enterprise wireless communication network
EP4323405A1 (de) 2021-04-12 2024-02-21 Incyte Corporation Kombinationstherapie mit einem fgfr-inhibitor und einem auf nectin-4 abzielenden mittel
EP4352059A1 (de) 2021-06-09 2024-04-17 Incyte Corporation Tricyclische heterocyclen als fgfr-inhibitoren

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914250A (en) 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
JPS608117B2 (ja) 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4452813A (en) 1981-05-22 1984-06-05 Taiho Pharmaceutical Company Limited Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
EP0136976A3 (de) 1983-08-23 1985-05-15 Ciba-Geigy Ag Verwendung von Phenylpyrimidinen als Pflanzenregulatoren
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5391571A (en) 1989-11-15 1995-02-21 American Home Products Corporation Cholesterol ester hydrolase inhibitors
US5081122A (en) 1990-03-05 1992-01-14 Sterling Drug Inc. Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof
US5112820A (en) 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
US4973587A (en) 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
US5013837A (en) 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5349056A (en) 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US5292736A (en) 1993-02-26 1994-03-08 Sterling Winthrop Inc. Morpholinoalkylindenes as antiglaucoma agents
FR2714057B1 (fr) 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
HUT78089A (hu) 1994-11-07 1999-08-30 Pfizer Inc. Neuropeptid Y1 receptorokhoz szelektíven kötődő szubsztituált piperazin-származékok
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
WO1996023517A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
JPH11501297A (ja) 1995-01-31 1999-02-02 イーライ・リリー・アンド・カンパニー 抗肥満症タンパク質
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
US5831115A (en) 1995-04-21 1998-11-03 Abbott Laboratories Inhibitors of squalene synthase and protein farnesyltransferase
US20020006964A1 (en) 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
US5739106A (en) 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
WO1997020823A2 (en) 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
AU1328197A (en) 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
AU7692896A (en) 1995-12-01 1997-06-27 Novartis Ag Quinazolin-2,4-diazirines as NPY receptor antagonist
WO1997020820A1 (en) 1995-12-01 1997-06-12 Novartis Ag Heteroaryl compounds
AU7692696A (en) 1995-12-01 1997-06-27 Novartis Ag Heteroaryl derivatives
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
EP0887340A4 (de) 1996-02-06 2000-03-29 Japan Tobacco Inc Chemische verbindungen und deren pharmazeutische verwendungen
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
AU7738198A (en) 1996-12-15 1998-07-15 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
ES2213892T3 (es) 1997-01-21 2004-09-01 Smithkline Beecham Corporation Nuevos moduladores del receptor de canabinoides.
KR100510794B1 (ko) 1997-02-04 2005-08-31 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 살진균 카르복스아미드
HU228509B1 (en) 1997-02-21 2013-03-28 Bayer Ip Gmbh Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
US5948777A (en) 1997-03-18 1999-09-07 Smithkline Beecham Corporation Cannabinoid receptor agonists
FR2761266B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
FR2761265B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
CA2288122C (en) 1997-04-23 2006-09-26 Banyu Pharmaceutical Co., Ltd. Neuropeptide y receptor antagonist
US6001836A (en) 1997-05-28 1999-12-14 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: cyanoguanidine derivatives
SE9702457D0 (sv) 1997-06-26 1997-06-26 Pharmacia & Upjohn Ab Screening
WO1999002499A1 (fr) 1997-07-11 1999-01-21 Japan Tobacco Inc. Composes quinoline et utilisations de ceux-ci en medecine
WO1999027965A1 (fr) 1997-11-28 1999-06-10 Banyu Pharmaceutical Co., Ltd. Agents anti-hyperlipemiques
EP1068207A1 (de) 1998-04-02 2001-01-17 Neurogen Corporation Aminoalkyl substituierte 9h-pyridino[2,3-b]indol- und 9h-pyrimidino[4,5-b]indol-derivate
RU2219167C2 (ru) 1998-04-29 2003-12-20 Орто-Макнейл Фармасьютикал, Инк. N-замещенные аминотетралины как лиганды для рецептора y5 нейропептида y, полезные при лечении ожирения и других расстройств
US6329395B1 (en) 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
CA2334551A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
HN1998000027A (es) 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
DE19837627A1 (de) 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
US6337332B1 (en) 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
DK1121111T3 (da) 1998-10-15 2010-05-31 Imp Innovations Ltd Forbindelser til behandling af vægttab
WO2000027845A1 (en) 1998-11-10 2000-05-18 Merck & Co., Inc. Spiro-indolines as y5 receptor antagonists
ES2161594B1 (es) 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
US6344481B1 (en) 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
ATE401066T1 (de) 1999-03-19 2008-08-15 Abbott Gmbh & Co Kg Methoden zur behandlung der essstörungen
FR2792314B1 (fr) 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE60034783T2 (de) 1999-04-22 2008-01-31 H. Lundbeck A/S, Valby Selektive npy(y5)-antagonisten
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
EP1177172A1 (de) 1999-05-05 2002-02-06 Ortho-McNeil Pharmaceutical, Inc. 3a,4,5,9b-tetrahydro-1h-benz[e]indol-2-yl amine-derivate als ligande von neuropeptide y rezeptoren zur behandlung der fettleibigkeit und andere störungen
US6291476B1 (en) 1999-05-12 2001-09-18 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
EP1187614A4 (de) 1999-06-04 2005-06-22 Merck & Co Inc Substituierte piperidine als melanocortin-4 rezeptoragonisten
CA2380866A1 (en) 1999-06-30 2001-01-11 Synaptic Pharmaceutical Corporation Selective npy (y5) antagonists
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
AR030676A1 (es) 1999-07-28 2003-09-03 Ortho Mcneil Pharm Inc Derivados de aminas y amidas como ligandos para el receptor del neuropeptido y y5 utiles en el tratamiento de la obesidad y otros trastornos, uso de los mismos para la elaboracion de medicamentos y composiciones farmaceuticas que los comprenden
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
KR20020047198A (ko) 1999-09-30 2002-06-21 해피 페너 ; 해리 에이치. 페너 2세 특정 알킬렌 디아민-치환된피라졸로[1,5-ａ]-1,5-피리미딘 및피라졸로[1,5-ａ]-1,3,5-트리아진
CZ20021086A3 (cs) 1999-09-30 2002-10-16 Neurogen Corporation Alkylendiaminem substituované heterocykly
AU7737900A (en) 1999-09-30 2001-04-30 Neurogen Corporation Amino substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines
IL149105A0 (en) 1999-10-13 2002-11-10 Pfizer Prodcts Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors
DE19949319A1 (de) 1999-10-13 2001-06-13 Ruetgers Vft Ag Verfahren zur Herstellung von Arylalkylethern
CZ20022100A3 (cs) 1999-12-16 2002-09-11 Schering Corporation Substituované imidazolové deriváty a farmaceutický prostředek
WO2001056592A1 (en) 2000-02-01 2001-08-09 Novo Nordisk A/S Use of compounds for the regulation of food intake
EP1254115A2 (de) 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid-rezeptor modulatoren, verfahren zu ihrer herstellung, und verwendung der cannabinoid-rezeptor modulatoren um respiratorische und nicht respiratorische krankheiten zu behandeln
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
EP1264826B1 (de) 2000-02-22 2005-03-30 Banyu Pharmaceutical Co., Ltd. Imidazolin-verbindungen
GB0004003D0 (en) 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
FR2805818B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805810B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805817B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
EP1132389A1 (de) 2000-03-06 2001-09-12 Vernalis Research Limited Neue Azaindolyl-Derivate für die Behandlung von Fettleibigheit
CA2402431C (en) 2000-03-14 2009-10-06 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinoline derivatives
CA2403631A1 (en) 2000-03-23 2001-09-27 Brenda L. Palucki Spiropiperidine derivatives as melanocortin receptor agonists
EP1268449A4 (de) 2000-03-23 2004-09-15 Merck & Co Inc Substituierte piperidine als melanokortin-rezeptor-agonisten
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
EP1142886A1 (de) 2000-04-07 2001-10-10 Aventis Pharma Deutschland GmbH Perzychinnin, Verfahren zu ihrer Herstellung und ihre Verwendung als pharmazeutisches Produkt
ATE479429T1 (de) 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
GB0011013D0 (en) 2000-05-09 2000-06-28 Astrazeneca Ab Chemical compounds
US6432960B2 (en) 2000-05-10 2002-08-13 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine NPY antagonists
US6479482B2 (en) 2000-05-10 2002-11-12 Bristol-Myers Squibb Company Alkylamine derivatives of dihydropyridine NPY antagonists
US6444675B2 (en) 2000-05-10 2002-09-03 Bristol-Myers Squibb Company 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists
BR0110638A (pt) 2000-05-11 2003-03-25 Bristol Myers Squibb Co Análogos de tetraidroisoquinolina úteis como secretagogos de hormÈnio do crescimento
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
WO2001087335A2 (en) 2000-05-17 2001-11-22 Eli Lilly And Company Method for selectively inhibiting ghrelin action
US6391881B2 (en) 2000-05-19 2002-05-21 Bristol-Myers Squibb Company Thiourea derivatives of dihydropyridine NPY antagonists
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
WO2001091752A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
EP2301930B1 (de) 2000-06-15 2016-01-06 Merck Sharp & Dohme Corp. Für Behandlung von unter anderem Autoimmun- oder entzündlichen Erkrankungen geeignete Derivate von Hexahydrobezofuranon
WO2001096302A1 (en) 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Piperidines for use as orexin receptor antagonists
AU783403B2 (en) 2000-07-05 2005-10-20 H. Lundbeck A/S Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
JP2004516239A (ja) 2000-07-06 2004-06-03 ニューロジェン コーポレイション メラニン凝集ホルモン受容体リガンド
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
KR20030033002A (ko) 2000-07-24 2003-04-26 아다나 바이오싸이언스 리미티드 그렐린 길항제
DK1325008T3 (da) 2000-07-31 2006-02-13 Hoffmann La Roche Piperazinderivater
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
AU2001288294A1 (en) 2000-08-21 2002-03-04 Merck And Co., Inc. Anti-hypercholesterolemic drug combination
US20040006120A1 (en) 2000-08-21 2004-01-08 Yates Stephen L Use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
US6767915B2 (en) 2000-08-23 2004-07-27 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
AU2001294547A1 (en) 2000-09-14 2002-03-26 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
WO2002032888A1 (en) 2000-10-13 2002-04-25 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
MXPA03003246A (es) 2000-10-16 2003-06-06 Hoffmann La Roche Derivados de indolina y su uso como ligandos del receptor 5-ht2.
PL362076A1 (en) 2000-10-20 2004-10-18 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
AU2002227170A1 (en) 2000-11-03 2002-05-15 Wyeth Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives
EP1337518B1 (de) 2000-11-20 2009-06-17 Biovitrum AB (publ) Piperazinylpyrazinverbindungen als antagonisten des serotonin-5-ht2-rezeptors
CN1267424C (zh) 2000-11-20 2006-08-02 比奥维特罗姆股份公司 作为5－羟色胺5ht－2受体的激动剂或拮抗剂的哌嗪基吡嗪化合物
DE60115092T2 (de) * 2000-12-12 2006-03-30 Neurogen Corp., Brandford Spiro[isobenzofuran-1,4'-piperidin]-3-one und 3h-spiroisobenzofuran-1,4'-piperidine
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
CA2432809C (en) 2000-12-21 2010-11-30 Schering Corporation Heteroaryl urea neuropeptide y y5 receptor antagonists
AU2002231097B2 (en) 2000-12-22 2004-12-09 Schering Corporation Piperidine MCH antagonists and their use in the treatment of obesity
ES2291374T3 (es) 2000-12-27 2008-03-01 F. Hoffmann-La Roche Ag Derivados de indol y su empleo como ligandos receptores de 5-ht2b y 5-ht2c.
WO2002051232A2 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
JP2004521117A (ja) 2001-01-23 2004-07-15 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニストとしての置換ピペリジン／ピペラジン
ES2246390T3 (es) 2001-01-23 2006-02-16 Eli Lilly And Company Derivados de piperazina como agonistas del receptor de melanocortina.
JP2004524297A (ja) 2001-01-23 2004-08-12 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニスト
CN1500080A (zh) 2001-02-02 2004-05-26 ����ҩƷ��ҵ��ʽ���� 稠合杂环化合物
WO2002068388A2 (en) 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2002067869A2 (en) 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2002068387A2 (en) 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
CA2441235C (en) 2001-03-21 2011-05-24 Pharmacopeia, Inc. Aryl and biaryl compounds having mch modulatory activity
MXPA03003534A (es) 2001-03-22 2005-01-25 Solvay Pharm Bv Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1.
WO2001074782A1 (en) 2001-03-29 2001-10-11 Molecular Design International, Inc. β3-ADRENORECEPTOR AGONISTS, AGONIST COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
CA2443672C (en) 2001-04-12 2011-03-29 Pharmacopeia, Inc. Aryl and biaryl piperidines used as mch antagonists
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
FR2824825B1 (fr) 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1395564B1 (de) 2001-05-21 2008-02-27 F. Hoffmann-La Roche Ag Chinolinderivate als liganden für den neuropeptid-y-rezeptor
WO2002094799A2 (en) 2001-05-22 2002-11-28 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
ATE381539T1 (de) 2001-06-20 2008-01-15 Merck & Co Inc Dipeptidylpeptidase-hemmer zur behandlung von diabetes
WO2003000181A2 (en) 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
ES2296962T3 (es) 2001-06-27 2008-05-01 Smithkline Beecham Corporation Pirrolidinas como inhibidores de dipeptidil peptidasa.
CN1990468A (zh) 2001-06-27 2007-07-04 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
DE60221983T2 (de) 2001-06-27 2008-05-15 Smithkline Beecham Corp. Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren
WO2003002593A2 (en) 2001-06-27 2003-01-09 Probiodrug Ag Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis
ATE388951T1 (de) 2001-07-03 2008-03-15 Novo Nordisk As Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
IL159697A0 (en) 2001-07-05 2004-06-20 Synaptic Pharma Corp Substituted anilinic piperidines as mch selective antagonists
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
ITMI20011483A1 (it) 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
DE60229393D1 (de) 2001-07-18 2008-11-27 Merck & Co Inc Überbrückte piperidinderivate als melanocortin-rezeptor-agonisten
WO2003007887A2 (en) 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US6915444B2 (en) 2001-09-12 2005-07-05 Rockwell Automation Technologies, Inc. Network independent safety protocol for industrial controller using data manipulation techniques
ATE433971T1 (de) * 2002-11-29 2009-07-15 Banyu Pharma Co Ltd Neue azolderivate

Also Published As

Publication number Publication date
DOP2003000662A (es) 2003-12-30
ECSP045505A (es) 2005-03-10
PE20040583A1 (es) 2004-10-04
WO2004002986A2 (en) 2004-01-08
CN100427486C (zh) 2008-10-22
IS7667A (is) 2005-01-27
HRP20041218A2 (en) 2005-04-30
PL374693A1 (en) 2005-10-31
TW200406411A (en) 2004-05-01
CA2490722A1 (en) 2004-01-08
CN1668615A (zh) 2005-09-14
US7803807B2 (en) 2010-09-28
WO2004002986A3 (en) 2004-04-22
US7687514B2 (en) 2010-03-30
EA200500103A1 (ru) 2005-06-30
CN100560585C (zh) 2009-11-18
US20100048600A1 (en) 2010-02-25
CN1955178A (zh) 2007-05-02
CA2490722C (en) 2012-05-01
IL165810A0 (en) 2006-01-15
EP1517908B1 (de) 2011-04-20
NO20050184L (no) 2005-01-12
AU2003248248B2 (en) 2009-03-12
AR040271A1 (es) 2005-03-23
US7105526B2 (en) 2006-09-12
RS113704A (en) 2007-02-05
MXPA04012731A (es) 2005-03-23
US20040054177A1 (en) 2004-03-18
ATE506360T1 (de) 2011-05-15
EP1517908A2 (de) 2005-03-30
BR0312066A (pt) 2005-03-29
US20060205750A1 (en) 2006-09-14
ZA200409339B (en) 2006-02-22
AU2003248248A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
DE60336811D1 (de) Neue benzimidazolderivate
DE60328671D1 (de) Neue aminobenzamidderivate
ATE421506T1 (de) Neue benzimidazolderivate
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
ATE450506T1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
ATE438644T1 (de) Chinazolinderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
DK1474408T3 (da) N-Phenyl-2-pyrimidinaminderivater
ATE386518T1 (de) Benzimidazolderivate
ATE340782T1 (de) Piperidinbenzolsulfonamidderivate
ATE352550T1 (de) Chinazolinderivate
DK1682493T3 (da) Amidoacetonitrilderivater
DK1606277T3 (da) Imidazol-4-yl-ethynyl-pyridinderivater
IS8364A (is) N-þíasól-2-ýl-bensamíð afleiður
ATE335729T1 (de) 3h-chinazoline -4-on derivaten
ATE423771T1 (de) Tetrahydrochinolinderivate
ATE457299T1 (de) 4-hydroxymethyl-1-aryl-cyclohexylamin-derivativ
DK1706373T3 (da) Amidoacetonitrilderivater
IS8045A (is) Púrín-6-ón-afleiður
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
DE50309081D1 (de) Neue diketopyrrolopyrrolpigmente
IS7906A (is) Afleiður própargýl-tríflúorómetoxý-amínó-benzóþíazóls
DE60323130D1 (de) Indolderivaten